Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL.

J Clin Oncol. 2006 Mar 1;24(7):1169-77.

2.

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

Ahmadzadeh M, Rosenberg SA.

Blood. 2006 Mar 15;107(6):2409-14. Epub 2005 Nov 22.

3.

Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.

Escobar A, López M, Serrano A, Ramirez M, Pérez C, Aguirre A, González R, Alfaro J, Larrondo M, Fodor M, Ferrada C, Salazar-Onfray F.

Clin Exp Immunol. 2005 Dec;142(3):555-68.

4.

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, Jove R, Pardoll D, Yu H.

Nat Med. 2005 Dec;11(12):1314-21. Epub 2005 Nov 20.

PMID:
16288283
5.

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen.

Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK.

J Exp Med. 2005 Nov 21;202(10):1375-86. Epub 2005 Nov 14.

6.

Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.

Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL.

Nat Med. 2005 Nov;11(11):1238-43. Epub 2005 Oct 16.

PMID:
16227988
7.

A function for interleukin 2 in Foxp3-expressing regulatory T cells.

Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY.

Nat Immunol. 2005 Nov;6(11):1142-51. Epub 2005 Oct 16. Erratum in: Nat Immunol. 2006 Apr;7(4):427.

PMID:
16227984
8.

Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus.

Watanabe N, Wang YH, Lee HK, Ito T, Wang YH, Cao W, Liu YJ.

Nature. 2005 Aug 25;436(7054):1181-5.

9.

IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease.

Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, Caligiuri MA.

Blood. 2005 Oct 1;106(7):2433-5. Epub 2005 Jun 23.

10.

Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.

Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J.

Blood. 2005 Oct 15;106(8):2903-11. Epub 2005 Jun 21.

11.

In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients.

Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, Berg SC, Metcalf JA, Hahn BK, Shen JM, Powers A, Davey RT, Kovacs JA, Shevach EM, Lane HC.

J Clin Invest. 2005 Jul;115(7):1839-47. Epub 2005 Jun 2.

12.

Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY.

Immunity. 2005 Mar;22(3):329-41.

13.
15.

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, Parekh J, Neese PY, Woodson EM, Wiernasz CJ, Merrill P.

J Clin Oncol. 2004 Nov 15;22(22):4474-85.

16.

Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification.

Nelson EA, Walker SR, Alvarez JV, Frank DA.

J Biol Chem. 2004 Dec 24;279(52):54724-30. Epub 2004 Oct 20.

17.

Tolerance, not immunity, crucially depends on IL-2.

Malek TR, Bayer AL.

Nat Rev Immunol. 2004 Sep;4(9):665-74. Review.

PMID:
15343366
18.

Interleukin-2 is essential for CD4+CD25+ regulatory T cell function.

de la Rosa M, Rutz S, Dorninger H, Scheffold A.

Eur J Immunol. 2004 Sep;34(9):2480-8.

19.

Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function.

Thornton AM, Donovan EE, Piccirillo CA, Shevach EM.

J Immunol. 2004 Jun 1;172(11):6519-23.

20.

Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells.

Bensinger SJ, Walsh PT, Zhang J, Carroll M, Parsons R, Rathmell JC, Thompson CB, Burchill MA, Farrar MA, Turka LA.

J Immunol. 2004 May 1;172(9):5287-96.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk